Tips for investing in COVID-19 vaccines developing stocks

Highlights 

  • The healthcare sector has exploded as pharmaceutical and biotech companies are in a race to develop COVID-19 vaccines, treatments, booster shots and more.
  • For investing in any vaccine developing companies, it is advisable to consider other products in development and drug candidates in the pipeline of the company.
  • Intellectual property waiver might impact the incentives for vaccine developers to conducting research, development and innovation.

The healthcare industry is witnessing rapid growth after the COVID-19 pandemic, with many companies engaged in developing vaccines, treatments, diagnostics and other protective measures to combat the pandemic.

Furthermore, the sector has exploded as pharmaceutical and biotech companies are in a race to develop COVID-19 vaccines, treatments, booster shots and more. In addition, the companies are using emerging technologies that can speed up the development of vaccines to combat other infectious disease.

Investing in COVID-19 vaccine

Many investors think that it is too late to invest in COVID-19 vaccine developing stocks, but it’s not. It seems like in some countries. The situation is better now because of the availability of vaccines. However, the outlook is not the same in all the countries across the world. Furthermore, the emergence of the new strains of coronavirus seems likely to fuel demand for vaccines for a long time to come.

Vaccine developers- MRNA, PFE, BNTX, AZN, JNJ, NVAX

Copyright © 2021 Kalkine Media

Here are some key points to keep in mind if anyone is watching vaccine stocks-

  • Though there are many companies in the market with a vaccine candidate in their product pipeline, few will win regulatory approvals. So, researching the vaccine developers and their vaccine candidates is always advisable.
  • Even vaccine developers that have received the required regulatory approvals may encounter various challenges that can ultimately prevent them from achieving commercial success.
  • For investing in any vaccine developing company, one should also consider other products and drug candidates in the pipeline.
  • The stocks of healthcare companies that have other successful products in the market are less risky than those that do not have other products.

Companies developing COVID-19 vaccine

  • Moderna (NASDAQ:MRNA)- US-based Moderna is developing mRNA based COVID-19 vaccine. Moderna’s vaccine obtained emergency use approval in December 2020. Now, the Company has also developed booster shots of its vaccine, which are under the consideration.
  • Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX)- Another mRNA based COVID-19 vaccine is developed by the duo Pfizer and BioNTech. The vaccine has received full approval from the US FDA in August 2021. Also, the booster shots of Pfizer-BioNTech’s COVID-19 vaccine are authorised by the FDA.
  • Johnson & Johnson (NASDAQ:JNJ)- The Company has developed its COVID-19 vaccine by using the AdVac® vaccine platform, and it is a single-dose COVID-19 vaccine. In February 2021, the vaccine obtained emergency use approval.
  • AstraZeneca (LON:AZN)- AstraZeneca was on the list of the early developer of the COVID-19 vaccine and is the biggest winner in the race. AstraZeneca’s vaccine is a viral vectored vaccine. The vaccine was granted Emergency Use Listing (EUL) by the World Health Organization (WHO) in February 2021.

Also, the vaccine has demonstrated 74% efficacy in large US clinical trials, and the Company will seek US authorisation for its vaccine this year.

  • Novavax (NASDAQ: NVAX)- Novavax is developing recombinant nanoparticle protein-based COVID-19 vaccine NVX-CoV2373. On 23 September 2021, Novavax and Serum Institute of India (SII) filed regulatory submission to the WHO for Emergency Use Listing (EUL) of the vaccine.

Apart from companies engaged in developing COVID-19 vaccines, many players in the space are developing oral and nasal delivery of COVID-19 vaccines. However, many experts are highlighting that to remain protected, booster shots are to be administered to people who are fully vaccinated. Hence, the vaccine developers are actively researching to develop and introduce booster shots for their COVID-19 vaccine.

Intellectual property waiver: an obstacle for COVID-19 vaccine developers

The countries are supporting intellectual property waiver for COVID-19 vaccine to manufacture the vaccine at multiple locations. It will also allow the low-income countries to manufacture and offer COVID-19 vaccine at lower cost to contain the spread of coronavirus. However, it can impact the profits for vaccine developers because after patent waiving there would not be any incentives for conducting research, development and innovation.

RELATED ARTICLE: Should pharmaceutical companies waive IP rights on COVID vaccines

Bottom Line

No one knows when the COVID-19 pandemic will end. However, this sector has exploded with healthcare companies in a race to develop and market novel COVID-19 vaccines, and booster shots. With nations in full swing with their COVID-19 vaccination drive and pandemic turning endemic in many regions, the future of vaccine candidate providers is yet to be ascertained.

RELATED ARTICLE: How long will COVID-19 pandemic last? Will it continue into 2022?

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK